126 related articles for article (PubMed ID: 24988931)
1. Cetuximab for resectable colorectal liver metastasis: new EPOC trial.
Hasegawa K; Oba M; Kokudo N
Lancet Oncol; 2014 Jul; 15(8):e305-6. PubMed ID: 24988931
[No Abstract] [Full Text] [Related]
2. Cetuximab for resectable colorectal liver metastasis: new EPOC trial--author's reply.
Primrose JN
Lancet Oncol; 2014 Jul; 15(8):e306. PubMed ID: 24988933
[No Abstract] [Full Text] [Related]
3. Adjuvant therapy after hepatectomy for colorectal metastases.
Fong Y
Lancet Oncol; 2014 May; 15(6):544-5. PubMed ID: 24807857
[No Abstract] [Full Text] [Related]
4. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
5. Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.
Sunakawa Y; Takahashi T; Ichikawa W; Shimada K; Sasaki Y
J Clin Oncol; 2013 Dec; 31(35):4473. PubMed ID: 24166514
[No Abstract] [Full Text] [Related]
6. Treatment of metastatic colon cancer: "the times they are A-changing".
Kemeny NE
J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
[No Abstract] [Full Text] [Related]
7. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
8. Surgery: Cetuximab--an option for unresectable CRC liver metastases.
Laurent-Puig P; Benhaim L
Nat Rev Clin Oncol; 2013 Jul; 10(7):374-5. PubMed ID: 23736647
[No Abstract] [Full Text] [Related]
9. An alternative therapy for patients with hepatic impairment?
Choo SP; Venook AP
Onkologie; 2007 Oct; 30(10):474-5. PubMed ID: 17890884
[No Abstract] [Full Text] [Related]
10. When inoperable becomes operable?
Mroczkowski P; Seidensticker M
J Clin Oncol; 2013 Dec; 31(35):4474. PubMed ID: 24166527
[No Abstract] [Full Text] [Related]
11. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
[TBL] [Abstract][Full Text] [Related]
12. Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
Nordlinger B; Poston GJ; Goldberg RM
J Clin Oncol; 2015 Jan; 33(3):241-3. PubMed ID: 25403221
[No Abstract] [Full Text] [Related]
13. [Systemic therapy for colorectal cancer].
Pestalozzi BC; Jäger D; Knuth A
Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F; Cunningham D
Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
[No Abstract] [Full Text] [Related]
15. Cetuximab in metastatic colorectal cancer.
Broadbridge VT; Karapetis CS; Price TJ
Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
[TBL] [Abstract][Full Text] [Related]
16. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
18. Reply to Y. Sunakawa et al and P. Mroczkowski et al.
Ye LC; Zhong YS; Lin Q; Xu J
J Clin Oncol; 2013 Dec; 31(35):4474-5. PubMed ID: 24166525
[No Abstract] [Full Text] [Related]
19. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
[TBL] [Abstract][Full Text] [Related]
20. Response phenotype as a predictive biomarker to guide treatment with targeted therapies.
Oxnard GR; Schwartz LH
J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
